Raymond S M Wong
Overview
Explore the profile of Raymond S M Wong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1995
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yap D, Chan G, Ho S, Wong R, Chan S, Lee V, et al.
Hum Vaccin Immunother
. 2025 Mar;
21(1):2463185.
PMID: 40063340
Patients with acquired immunocompromising conditions face considerable risk of developing herpes zoster (HZ). Based on the underlying medical conditions and degree of immune dysfunction, these patients require tailored strategies for...
2.
Bai J, Jiang P, Ji L, Lam W, Zhou Q, Ma M, et al.
Proc Natl Acad Sci U S A
. 2024 Oct;
121(42):e2404058121.
PMID: 39382996
The analysis of tissues of origin of cell-free DNA (cfDNA) is of research and diagnostic interest. Many studies focused on bisulfite treatment or immunoprecipitation protocols to assess the tissues of...
3.
Lam W, Gai W, Bai J, Tam T, Cheung W, Ji L, et al.
NPJ Genom Med
. 2024 Aug;
9(1):39.
PMID: 39103426
The tissues of origin of plasma DNA can be revealed by methylation patterns. However, the relative DNA contributions from megakaryocytes and erythroblasts into plasma appeared inconsistent among studies. To shed...
4.
Fan X, Cao K, Wong R, Yan X
Drug Deliv Transl Res
. 2024 Jul;
15(4):1109-1120.
PMID: 39048784
Iron is essential for every cell of the mammalian organism. Iron deficiency is a major public health issue worldwide. Intravenous (IV) iron therapy has been used to treat anemia. However,...
5.
Zou H, Wong R, Yan X
Clin Exp Pharmacol Physiol
. 2024 May;
51(6):e13869.
PMID: 38725222
Treatment with erythropoietin (EPO) can correct anaemia in chronic kidney disease (CKD) patients; however, up to 10% exhibit resistance or hyporesponsiveness to EPO. Non-alcoholic fatty liver disease (NAFLD), prevalent liver...
6.
Xu P, Wong R, Yan X
Br J Pharmacol
. 2024 Apr;
181(16):2833-2850.
PMID: 38653449
Background And Purpose: Our previous study reported that erythroferrone (ERFE), a newly identified hormone produced by erythroblasts, responded to recombinant human erythropoietin (rHuEPO) sensitively but its dynamics was complicated by...
7.
Shi M, Yang A, Lau E, Luk A, Ma R, Kong A, et al.
PLoS Med
. 2024 Apr;
21(4):e1004369.
PMID: 38607977
Background: Older adults with diabetes are at high risk of severe hypoglycemia (SH). Many machine-learning (ML) models predict short-term hypoglycemia are not specific for older adults and show poor precision-recall....
8.
Zou H, Wong R, Yan X
Biochem Pharmacol
. 2023 Dec;
220:116008.
PMID: 38154543
Recombinant human erythropoietin (rHuEPO) is a prevalent treatment for anemia in patients with chronic kidney disease. However, up to 10% of these patients exhibit EPO resistance or hyporesponsiveness, which may...
9.
Fan X, Krzyzanski W, Wong R, Liu D, Yan X
ACS Pharmacol Transl Sci
. 2023 Dec;
6(12):1884-1897.
PMID: 38093847
Chemotherapy-induced anemia and thrombocytopenia (CIAT) in cancer patients are often caused by the damage of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow. We have previously shown that...
10.
Xu P, Wong R, Yan X
J Pharm Sci
. 2023 Nov;
113(1):246-256.
PMID: 37913904
Erythropoiesis-stimulating agents (ESAs) have been a common treatment for anemia associated with chronic kidney disease (CKD), while 10-20 % of patients continue to suffer from persistent anemia despite receiving ESA...